

Rev03 DATASHEET

Update: Dec,14,2021

IGF-BP-2, His, Human

Cat. No.: Z03201

Product Introduction

Species	Human	
Protein Construction	IGF-BP-2 (Phe40-Gln325) Accession # P18065 Poly-His	
	N-term C-term	
Purity	> 95% as analyzed by SDS-PAGE	
Endotoxin Level	$<$ 0.2 EU/ μg of protein by gel clotting method	
Biological Activity	$ED_{50}{<}2.0~\mu g/ml,$ measured in a bioassay using FDC-P1 cells in the presence of 15.0 ng/ml human IGF-II.	
Expression System	HEK 293	
Apparent Molecular Weight	6~20 kDa, on SDS-PAGE under reducing conditions.	
Formulation	Lyophilized after extensive dialysis against PBS.	
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml.	
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.	

Background

Target Background: IGF-BP-2, also known as Insulin-like growth factor-binding protein 2, IBP-2 and BP-2, is a cysteine-rich secreted protein belonging to the IGF-binding protein superfamily. It is expressed by the central nervous system, bone cells and reproductive tissues. IGF-BP-2 binds to both IGF-I and IGF-II, with a much higher binding affinity to IGF-II than IGF-I. IGF-BP-2 has been shown to inhibitand stimulate the growth promoting effects of IGFs, thus serving as a regulator for IGF distribution, function and activity.

Synonyms: Insulin-like growth factor-binding protein 2; IBP-2; BP-2



For laboratory research use only. Direct human use, including taking orally and injection and clir orbidden.	nical use are